Kilani Holding Explores Export Opportunities in Oman
Kilani Holding, the owner of Tunisian pharmaceutical laboratory Adwya, has initiated a prospecting phase in the Sultanate of Oman to evaluate opportunities for exporting medicines and potentially investing in the Omani pharmaceutical sector.
Confirmation of Talks
This information was confirmed following a meeting held on December 1 between the Omani ambassador to Tunisia, the CEO of Kilani Holding, Sarra Masmoudi, and the CEO of Adwya, Asma Al-Salami. The meeting discussed potential cooperation between the two parties in the pharmaceutical field.
Priorities and Future Plans
According to Kilani Holding's management, the current priority is to export products manufactured by Adwya to the Omani market. The possibility of local investment or industrial establishment is not ruled out but remains conditional on ongoing studies and discussions with Omani authorities.
Background and Context
Adwya, one of the leading Tunisian laboratories, was acquired by Kilani Holding in 2022. The group is now seeking to strengthen its international presence, particularly in the Gulf region, where markets are showing increasing demand for generic medicines.
Next Steps
No final decision has been announced yet, with exchanges currently limited to an initial phase of exploration and framing. Kilani Holding's move into the Omani market marks a significant step in its expansion strategy, aiming to capitalize on the growing demand for pharmaceuticals in the region.
